122 related articles for article (PubMed ID: 16954995)
1. In vivo detection of head and neck cancer orthotopic xenografts by immunofluorescence.
Rosenthal EL; Kulbersh BD; Duncan RD; Zhang W; Magnuson JS; Carroll WR; Zinn K
Laryngoscope; 2006 Sep; 116(9):1636-41. PubMed ID: 16954995
[TBL] [Abstract][Full Text] [Related]
2. Use of fluorescent labeled anti-epidermal growth factor receptor antibody to image head and neck squamous cell carcinoma xenografts.
Rosenthal EL; Kulbersh BD; King T; Chaudhuri TR; Zinn KR
Mol Cancer Ther; 2007 Apr; 6(4):1230-8. PubMed ID: 17431103
[TBL] [Abstract][Full Text] [Related]
3. Stereomicroscopic fluorescence imaging of head and neck cancer xenografts targeting CD147.
Newman JR; Gleysteen JP; Barañano CF; Bremser JR; Zhang W; Zinn KR; Rosenthal EL
Cancer Biol Ther; 2008 Jul; 7(7):1063-70. PubMed ID: 18431087
[TBL] [Abstract][Full Text] [Related]
4. Sensitivity and specificity of fluorescent immunoguided neoplasm detection in head and neck cancer xenografts.
Kulbersh BD; Duncan RD; Magnuson JS; Skipper JB; Zinn K; Rosenthal EL
Arch Otolaryngol Head Neck Surg; 2007 May; 133(5):511-5. PubMed ID: 17520766
[TBL] [Abstract][Full Text] [Related]
5. Optical imaging predicts tumor response to anti-EGFR therapy.
Helman EE; Newman JR; Dean NR; Zhang W; Zinn KR; Rosenthal EL
Cancer Biol Ther; 2010 Jul; 10(2):166-71. PubMed ID: 20505368
[TBL] [Abstract][Full Text] [Related]
6. Assessment of bevacizumab conjugated to Cy5.5 for detection of head and neck cancer xenografts.
Withrow KP; Newman JR; Skipper JB; Gleysteen JP; Magnuson JS; Zinn K; Rosenthal EL
Technol Cancer Res Treat; 2008 Feb; 7(1):61-6. PubMed ID: 18198926
[TBL] [Abstract][Full Text] [Related]
7. Assessment of indocyanine green-labeled cetuximab to detect xenografted head and neck cancer cell lines.
Withrow KP; Gleysteen JP; Safavy A; Skipper J; Desmond RA; Zinn K; Rosenthal EL
Otolaryngol Head Neck Surg; 2007 Nov; 137(5):729-34. PubMed ID: 17967636
[TBL] [Abstract][Full Text] [Related]
8. Fluorescent labeled anti-EGFR antibody for identification of regional and distant metastasis in a preclinical xenograft model.
Gleysteen JP; Newman JR; Chhieng D; Frost A; Zinn KR; Rosenthal EL
Head Neck; 2008 Jun; 30(6):782-9. PubMed ID: 18228526
[TBL] [Abstract][Full Text] [Related]
9. Imaging of epidermal growth factor receptor expression in head and neck cancer with SPECT/CT and 111In-labeled cetuximab-F(ab')2.
van Dijk LK; Hoeben BA; Kaanders JH; Franssen GM; Boerman OC; Bussink J
J Nucl Med; 2013 Dec; 54(12):2118-24. PubMed ID: 24136932
[TBL] [Abstract][Full Text] [Related]
10. Preclinical comparison of near-infrared-labeled cetuximab and panitumumab for optical imaging of head and neck squamous cell carcinoma.
Day KE; Sweeny L; Kulbersh B; Zinn KR; Rosenthal EL
Mol Imaging Biol; 2013 Dec; 15(6):722-9. PubMed ID: 23715932
[TBL] [Abstract][Full Text] [Related]
11. Use of panitumumab-IRDye800 to image microscopic head and neck cancer in an orthotopic surgical model.
Heath CH; Deep NL; Sweeny L; Zinn KR; Rosenthal EL
Ann Surg Oncol; 2012 Nov; 19(12):3879-87. PubMed ID: 22669455
[TBL] [Abstract][Full Text] [Related]
12. Near-infrared optical imaging of epidermal growth factor receptor in breast cancer xenografts.
Ke S; Wen X; Gurfinkel M; Charnsangavej C; Wallace S; Sevick-Muraca EM; Li C
Cancer Res; 2003 Nov; 63(22):7870-5. PubMed ID: 14633715
[TBL] [Abstract][Full Text] [Related]
13. In vivo diagnosis of epidermal growth factor receptor expression using molecular imaging with a cocktail of optically labeled monoclonal antibodies.
Barrett T; Koyama Y; Hama Y; Ravizzini G; Shin IS; Jang BS; Paik CH; Urano Y; Choyke PL; Kobayashi H
Clin Cancer Res; 2007 Nov; 13(22 Pt 1):6639-48. PubMed ID: 17982120
[TBL] [Abstract][Full Text] [Related]
14. Radioimmunotherapy of head and neck cancer xenografts using 131I-labeled antibody L19-SIP for selective targeting of tumor vasculature.
Tijink BM; Neri D; Leemans CR; Budde M; Dinkelborg LM; Stigter-van Walsum M; Zardi L; van Dongen GA
J Nucl Med; 2006 Jul; 47(7):1127-35. PubMed ID: 16818947
[TBL] [Abstract][Full Text] [Related]
15. Characterizing breast cancer xenograft epidermal growth factor receptor expression by using near-infrared optical imaging.
Wang K; Wang K; Li W; Huang T; Li R; Wang D; Shen B; Chen X
Acta Radiol; 2009 Dec; 50(10):1095-103. PubMed ID: 19922304
[TBL] [Abstract][Full Text] [Related]
16. Preclinical evaluation of near-infrared (NIR) fluorescently labeled cetuximab as a potential tool for fluorescence-guided surgery.
Saccomano M; Dullin C; Alves F; Napp J
Int J Cancer; 2016 Nov; 139(10):2277-89. PubMed ID: 27428782
[TBL] [Abstract][Full Text] [Related]
17. Fluorescently labeled cetuximab to evaluate head and neck cancer response to treatment.
Gleysteen JP; Duncan RD; Magnuson JS; Skipper JB; Zinn K; Rosenthal EL
Cancer Biol Ther; 2007 Aug; 6(8):1181-5. PubMed ID: 17637562
[TBL] [Abstract][Full Text] [Related]
18. The effects of cetuximab alone and in combination with radiation and/or chemotherapy in lung cancer.
Raben D; Helfrich B; Chan DC; Ciardiello F; Zhao L; Franklin W; Barón AE; Zeng C; Johnson TK; Bunn PA
Clin Cancer Res; 2005 Jan; 11(2 Pt 1):795-805. PubMed ID: 15701870
[TBL] [Abstract][Full Text] [Related]
19. Inactivation of HNSCC cells by 90Y-labeled cetuximab strictly depends on the number of induced DNA double-strand breaks.
Saker J; Kriegs M; Zenker M; Heldt JM; Eke I; Pietzsch HJ; Grénman R; Cordes N; Petersen C; Baumann M; Steinbach J; Dikomey E; Kasten-Pisula U
J Nucl Med; 2013 Mar; 54(3):416-23. PubMed ID: 23345302
[TBL] [Abstract][Full Text] [Related]
20. In vivo molecular imaging to diagnose and subtype tumors through receptor-targeted optically labeled monoclonal antibodies.
Koyama Y; Barrett T; Hama Y; Ravizzini G; Choyke PL; Kobayashi H
Neoplasia; 2007 Dec; 9(12):1021-9. PubMed ID: 18084609
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
